AR078781A2 - Composicion farmaceutica solida adecuada para administracion oral - Google Patents

Composicion farmaceutica solida adecuada para administracion oral

Info

Publication number
AR078781A2
AR078781A2 ARP100103930A ARP100103930A AR078781A2 AR 078781 A2 AR078781 A2 AR 078781A2 AR P100103930 A ARP100103930 A AR P100103930A AR P100103930 A ARP100103930 A AR P100103930A AR 078781 A2 AR078781 A2 AR 078781A2
Authority
AR
Argentina
Prior art keywords
mannitol
oral administration
pharmaceutical composition
solid pharmaceutical
composition
Prior art date
Application number
ARP100103930A
Other languages
English (en)
Original Assignee
Mitsubishi Tanabe Pharma Corp
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR078781(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Tanabe Pharma Corp, Novartis Ag filed Critical Mitsubishi Tanabe Pharma Corp
Publication of AR078781A2 publication Critical patent/AR078781A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composicion farmacéutica solida adecuada para administracion oral, que comprende: (a) un agonista del receptor de S1P; y (b) manitol, donde la composicion es una forma de dosificacion solida, el manitol tiene un área superficial específica alta y el agonista del receptor de S1P se selecciona de 2-amino-2-[2-(4-(octilfenil)etil]propano-1,3-diol (FTY720), una sal farmacéuticamente aceptable del mismo, y FTY720-fosfato. Reivindicacion 5: Una composicion de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizada porque el manitol tiene un tamano de partícula promedio de 100 a 300 micrometros o 150 a 250 micrometros. Reivindicacion 12: Una composicion de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizada porque comprende de 90 a 99,5% en peso de manitol. Reivindicacion 13: Una composicion de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizada porque la composicion es una forma de dosificacion unitaria y contiene 0,5 a 10 mg del antagonista del receptor de S1P.
ARP100103930A 2003-04-08 2010-10-26 Composicion farmaceutica solida adecuada para administracion oral AR078781A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08

Publications (1)

Publication Number Publication Date
AR078781A2 true AR078781A2 (es) 2011-11-30

Family

ID=32326722

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP040101162A AR043987A1 (es) 2003-04-08 2004-04-06 Composiciones farmaceuticas para administracion oral de agonistas del receptor de fosfato de esfingosina-1
ARP100103930A AR078781A2 (es) 2003-04-08 2010-10-26 Composicion farmaceutica solida adecuada para administracion oral
ARP100103931A AR078782A2 (es) 2003-04-08 2010-10-26 Procedimiento para producir una composicion farmaceutica que comprende un agonista del receptor de fosfato de esfingosina-1 (s1p)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP040101162A AR043987A1 (es) 2003-04-08 2004-04-06 Composiciones farmaceuticas para administracion oral de agonistas del receptor de fosfato de esfingosina-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP100103931A AR078782A2 (es) 2003-04-08 2010-10-26 Procedimiento para producir una composicion farmaceutica que comprende un agonista del receptor de fosfato de esfingosina-1 (s1p)

Country Status (41)

Country Link
US (11) US20060275357A1 (es)
EP (5) EP2769713A1 (es)
JP (3) JP5495467B2 (es)
KR (3) KR20050121712A (es)
CN (2) CN101797241B (es)
AR (3) AR043987A1 (es)
AT (3) AT501681B1 (es)
AU (1) AU2004228929B2 (es)
BE (2) BE1015972A5 (es)
BR (1) BRPI0409250B8 (es)
CA (2) CA2521325C (es)
CL (2) CL2004000745A1 (es)
CY (3) CY1110260T1 (es)
DE (4) DE202004021680U1 (es)
DK (2) DK1613288T3 (es)
EC (1) ECSP056090A (es)
ES (3) ES2320767T3 (es)
FR (2) FR2854073B1 (es)
GB (1) GB2400318B (es)
GR (1) GR1005052B (es)
HR (3) HRP20100600A2 (es)
HU (2) HUE028247T2 (es)
IL (3) IL170888A (es)
IS (2) IS2682B (es)
IT (1) ITMI20040682A1 (es)
LU (1) LU91867I2 (es)
MA (1) MA27729A1 (es)
MX (1) MXPA05010860A (es)
MY (1) MY141249A (es)
NO (4) NO329332B1 (es)
NZ (3) NZ542622A (es)
PE (5) PE20090743A1 (es)
PL (2) PL2316431T3 (es)
PT (1) PT1613288E (es)
RU (5) RU2358716C2 (es)
SG (1) SG175449A1 (es)
SI (2) SI1613288T1 (es)
TN (1) TNSN05256A1 (es)
TW (1) TWI332847B (es)
WO (1) WO2004089341A1 (es)
ZA (1) ZA200507394B (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096972A1 (en) * 2004-07-30 2008-04-24 Thitiwan Buranachokpaisan Compound formulations of 2-amino-1, 3-propanediol compounds
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
PL1926483T3 (pl) * 2005-09-09 2011-05-31 Novartis Ag Leczenie chorób autoimmunologicznych
US8716322B2 (en) 2005-11-09 2014-05-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
NZ597545A (en) 2006-06-19 2013-07-26 Proteolix Inc Peptide epoxyketones for proteasome inhibition
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
PT3103448T (pt) * 2006-09-26 2019-07-12 Novartis Ag Composições farmacêuticas que compreendem um modulador de s1p
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
MY149356A (en) 2007-03-29 2013-08-30 Daiichi Sankyo Co Ltd Pharmaceutical composition
JP5734656B2 (ja) 2007-10-04 2015-06-17 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤結晶及びアミノ酸ケトエポキシドの調製
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
TW200927142A (en) * 2007-10-12 2009-07-01 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
US8476305B2 (en) 2008-02-07 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient
DK2278960T4 (da) 2008-03-17 2020-01-27 Actelion Pharmaceuticals Ltd Dosisregimen til en selektiv sip1 receptoragonist
ES2676288T3 (es) * 2008-06-20 2018-07-18 Merck Patent Gmbh Matriz de comprimidos directamente compresible y rápidamente desintegrable
CN104800196A (zh) 2008-06-20 2015-07-29 诺华股份有限公司 用于治疗多发性硬化的儿科组合物
WO2010025796A1 (en) * 2008-09-04 2010-03-11 Cargill Incorporated Tabletting of ervthritol
EA024364B1 (ru) 2008-10-21 2016-09-30 Оникс Терапьютикс, Инк. Способ лечения множественной миеломы
CA2741974A1 (en) 2008-11-11 2010-05-20 Novartis Ag Salts of fingolimod
AU2013100532B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
BRPI0921826A2 (pt) * 2008-11-11 2016-01-12 Novartis Ag compostos orgânicos
BRPI0923109A8 (pt) 2008-12-17 2016-06-07 Daiichi Sankyo Co Ltd método para a produção de derivados de diamina
WO2010082531A1 (ja) 2009-01-13 2010-07-22 第一三共株式会社 活性化血液凝固因子阻害剤
CN102348688B (zh) 2009-03-10 2014-07-09 第一三共株式会社 用于制备二胺衍生物的方法
CN102348680B (zh) 2009-03-13 2014-11-05 第一三共株式会社 用于制备光学活性二胺衍生物的方法
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
TW201102064A (en) * 2009-06-18 2011-01-16 Daiichi Sankyo Co Ltd Pharmaceutical composition having improved dissolution property
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
CA2791651C (en) 2010-03-01 2019-08-20 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
KR101792299B1 (ko) 2010-03-19 2017-10-31 다이이찌 산쿄 가부시키가이샤 항응고제의 용출 개선 방법
CN102791719B (zh) 2010-03-19 2015-07-29 第一三共株式会社 二胺衍生物的晶体及其制备方法
EP2560619A2 (en) * 2010-04-22 2013-02-27 Ratiopharm GmbH A method of preparing an oral dosage form comprising fingolimod
EP2589590B1 (en) 2010-07-02 2016-12-28 Daiichi Sankyo Company, Limited Process for preparation of optically active diamine derivative salt
EP2646409A4 (en) 2010-11-25 2015-12-16 Shilpa Medicare Ltd FINGOLIMOD POLYMORPHES AND METHOD THEREFOR
PH12013501442B1 (en) 2011-01-07 2018-04-20 Novartis Ag Immunosuppressant formulations
US8858991B2 (en) 2011-01-19 2014-10-14 Pathologica Llc Delayed release oral pharmaceutical dosage forms comprising MGBG
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
EP2739272A1 (en) 2011-08-01 2014-06-11 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
TWI578988B (zh) 2011-08-10 2017-04-21 第一三共股份有限公司 含二胺衍生物之醫藥組成物
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
AU2014205529B2 (en) * 2013-01-08 2018-08-09 Pathologica Llc Methods and compositions for treatment of demyelinating diseases
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
EP2990055B1 (en) * 2013-04-26 2019-06-05 Kyoto University Composition comprising a sphingosine-1-phosphate receptor 1 agonist for inhibiting formation and/or enlargement of cerebral aneurysm or for shrinking it
WO2013190151A1 (en) * 2013-05-13 2013-12-27 Synthon B.V. Pharmaceutical composition comprising fingolimod
US20160128951A1 (en) * 2013-07-29 2016-05-12 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2016026461A1 (en) * 2014-08-22 2016-02-25 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
EP3247341A4 (en) * 2015-01-20 2018-12-19 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
WO2018178744A1 (en) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) * 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
MX2022015003A (es) 2020-05-29 2023-03-03 Myovant Sciences Gmbh Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina.
WO2022015348A1 (en) 2020-07-16 2022-01-20 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection
AU2022214268A1 (en) * 2021-01-28 2023-07-27 Priothera Limited Methods of treatment with s1p receptor modulators
WO2022162409A1 (en) * 2021-01-28 2022-08-04 Priothera Sas Methods of treatment with s1p receptor modulators

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
WO1994008943A1 (fr) * 1992-10-21 1994-04-28 Yoshitomi Pharmaceutical Industries, Ltd. Compose 2-amino-1,3-propanediol et immunosuppresseur
ATE211726T1 (de) 1994-08-22 2002-01-15 Welfide Corp Benzolderivate und deren medizinische verwendung
HU224814B1 (en) 1995-12-28 2006-02-28 Mitsubishi Pharma Corp Use of propane-1,3-diol derivative for the preparation of a medicament useful for the topical treating of inflammatory and immune diseases
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JPH11209277A (ja) 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
KR20000075745A (ko) * 1997-02-27 2000-12-26 가마후라 아키오 의약 조성물
USRE39072E1 (en) * 1997-04-04 2006-04-18 Mitsubishi Pharma Corporation 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
WO2001003739A1 (fr) * 1999-07-12 2001-01-18 Ono Pharmaceutical Co., Ltd. Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
EP1300405B1 (en) 2000-07-13 2007-04-18 Sankyo Company, Limited Amino alcohol derivatives
EP1315735A4 (en) 2000-08-31 2005-04-06 Merck & Co Inc Phosphate derivatives as immunoregulatory compounds
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
MXPA03008755A (es) 2001-03-26 2004-02-18 Novartis Ag Derivados de 2-amino-propanol.
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
EP1424078A4 (en) 2001-09-04 2009-03-25 Ono Pharmaceutical Co RESPIRATORY DISEASE MEDICINES COMPRISING A SPHINGOSINE-1-PHOSPHATE RECEPTOR REGULATING AGENT
CA2461212C (en) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
DE60235900D1 (de) 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
ATE441654T1 (de) 2002-01-18 2009-09-15 Merck & Co Inc Edg-rezeptoragonisten
US20050070506A1 (en) 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
JP2005519915A (ja) 2002-01-18 2005-07-07 セレテック・リミテッド・ライアビリティ・カンパニー Ｅｄｇ受容体に関連する症状の処置方法
AU2003202994B2 (en) 2002-01-18 2007-11-22 Merck Sharp & Dohme Corp. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
US7781617B2 (en) * 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect

Also Published As

Publication number Publication date
BE2011C030I2 (es) 2023-03-07
RU2475236C2 (ru) 2013-02-20
FR11C0036I2 (fr) 2023-12-29
HRP20050886B1 (en) 2011-01-31
EP2319502A1 (en) 2011-05-11
DE202004021680U1 (de) 2010-04-22
AU2004228929A1 (en) 2004-10-21
DE122011100047I1 (de) 2011-12-15
US20140011885A1 (en) 2014-01-09
CY2011013I2 (el) 2014-04-09
HUS1100016I1 (hu) 2016-08-29
US20140255497A1 (en) 2014-09-11
NO20055231D0 (no) 2005-11-07
PE20150676A1 (es) 2015-05-17
DE102004016947A1 (de) 2004-10-21
EP2008650A2 (en) 2008-12-31
AT501681B1 (de) 2012-04-15
IL242037A0 (en) 2015-11-30
DK1613288T3 (da) 2009-03-23
EP1613288B1 (en) 2008-11-19
EP1613288A1 (en) 2006-01-11
IS8114A (is) 2005-11-01
NO20131287L (no) 2006-01-09
RU2010147000A (ru) 2012-08-10
US20190175527A1 (en) 2019-06-13
ES2556947T3 (es) 2016-01-21
NO20100250L (no) 2006-01-09
US8324283B2 (en) 2012-12-04
ES2320767T3 (es) 2009-05-28
US20090203798A1 (en) 2009-08-13
PE20131352A1 (es) 2013-11-14
LU91867I9 (es) 2019-01-03
SG175449A1 (en) 2011-11-28
AU2004228929B2 (en) 2008-02-07
AT504853A2 (de) 2008-08-15
KR20050121712A (ko) 2005-12-27
ITMI20040682A1 (it) 2004-07-06
RU2005134173A (ru) 2006-09-10
AR043987A1 (es) 2005-08-17
PE20130200A1 (es) 2013-03-09
IL197578A0 (en) 2011-07-31
ZA200507394B (en) 2007-03-28
HRP20100600A2 (hr) 2011-03-31
US20110105620A1 (en) 2011-05-05
CN101797241B (zh) 2013-03-27
EP2316431A1 (en) 2011-05-04
HK1071685A1 (en) 2005-07-29
HK1091114A1 (en) 2007-01-12
HRP20100601B1 (hr) 2016-12-02
LU91867I2 (fr) 2011-11-08
CY2011013I1 (el) 2014-04-09
PE20090743A1 (es) 2009-07-17
JP5543298B2 (ja) 2014-07-09
CN1767819A (zh) 2006-05-03
EP2008650A3 (en) 2011-04-27
HK1155647A1 (en) 2012-05-25
TW200503784A (en) 2005-02-01
CA2521325A1 (en) 2004-10-21
EP2316431B1 (en) 2015-09-30
FR2854073A1 (fr) 2004-10-29
ES2228282B1 (es) 2006-02-16
US20060275357A1 (en) 2006-12-07
IS2682B (is) 2010-10-15
TWI332847B (en) 2010-11-11
CY1110260T1 (el) 2014-04-09
GB2400318A (en) 2004-10-13
IS8885A (is) 2010-02-25
JP5495467B2 (ja) 2014-05-21
AR078782A2 (es) 2011-11-30
US20220031609A1 (en) 2022-02-03
BRPI0409250B1 (pt) 2017-07-11
CA2521325C (en) 2010-09-14
EP2769713A1 (en) 2014-08-27
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
NO2011016I2 (no) 2012-08-27
CN101797241A (zh) 2010-08-11
GR20040100121A (el) 2004-12-17
DE602004017847D1 (de) 2009-01-02
NO329332B1 (no) 2010-09-27
US20200237690A1 (en) 2020-07-30
PL1613288T3 (pl) 2009-07-31
US20170290787A1 (en) 2017-10-12
FR11C0036I1 (fr) 2011-10-14
JP2004307506A (ja) 2004-11-04
HRP20100601A2 (hr) 2011-03-31
US20080311188A1 (en) 2008-12-18
SI2316431T1 (sl) 2016-04-29
HRP20050886A2 (en) 2006-11-30
CN1767819B (zh) 2010-07-28
AT501681A1 (de) 2006-10-15
KR20120101148A (ko) 2012-09-12
BRPI0409250A (pt) 2006-03-28
NZ542622A (en) 2009-01-31
ES2228282A1 (es) 2005-04-01
GB2400318B (en) 2005-08-10
BRPI0409250B8 (pt) 2022-01-18
KR20110005320A (ko) 2011-01-17
NZ586280A (en) 2011-12-22
JP2011006461A (ja) 2011-01-13
RU2358716C2 (ru) 2009-06-20
PE20050396A1 (es) 2005-07-05
NO334116B1 (no) 2013-12-16
RU2010146697A (ru) 2012-05-27
FR2854073B1 (fr) 2008-03-14
KR101367574B1 (ko) 2014-02-25
ATE414508T1 (de) 2008-12-15
HUE028247T2 (en) 2016-12-28
IL170888A (en) 2010-06-16
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
JP2013177404A (ja) 2013-09-09
US20130108675A1 (en) 2013-05-02
MXPA05010860A (es) 2006-05-25
RU2009105403A (ru) 2010-08-27
NO2011016I1 (no) 2011-09-19
ECSP056090A (es) 2006-03-01
TNSN05256A1 (en) 2007-07-10
WO2004089341A1 (en) 2004-10-21
PT1613288E (pt) 2009-02-25
IL197578A (en) 2015-10-29
CA2707750A1 (en) 2004-10-21
CY1117071T1 (el) 2017-04-05
GB0407819D0 (en) 2004-05-12
NZ592339A (en) 2012-09-28
NO335120B1 (no) 2014-09-22
RU2475237C2 (ru) 2013-02-20
CL2004000745A1 (es) 2005-02-11
DK2316431T3 (en) 2016-01-11
RU2012148593A (ru) 2014-05-20
GR1005052B (el) 2005-11-30
SI1613288T1 (sl) 2009-04-30
MY141249A (en) 2010-03-31
MA27729A1 (fr) 2006-01-02
IE20040246A1 (en) 2004-12-15

Similar Documents

Publication Publication Date Title
AR078781A2 (es) Composicion farmaceutica solida adecuada para administracion oral
ES2551307T3 (es) Composición de inhalación que contiene aclidinio para tratamiento de enfermedad pulmonar obstructiva crónica
AR110010A2 (es) Composición farmacéutica formulada en una forma de dosis única de 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo
CO2019001895A2 (es) Formulación novedosa para administración por vía oral
ES2178943B1 (es) Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica.
CO6321225A2 (es) Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico
CU23468B7 (es) Forma de dosificación de pramipexol en una dosis única diaria
CO5390076A1 (es) Composiciones farmaceuticas
UY30537A1 (es) Formulaciones de flibanserina y metodo para fabricarlas
PE20020770A1 (es) Formulaciones de entecavir de dosis bajas y uso
ECSP066807A (es) Formulaciones galénicas de compuestos orgánicos
CO5280073A1 (es) Composiciones
UY30440A1 (es) Nuevos compuestos
PE20081297A1 (es) Forma de dosificacion transdermica resistente a la manipulacion
CA2410311A1 (en) Barbituric acid analogs as therapeutic agents
RU2007127999A (ru) Орально распадающееся фармацевтические композиции с сенсорными сигнальными агентами
AR054833A1 (es) Formas de dosificacion de liberacion retardada oral altamemte biodisponibles de succinato de o-desmetilvenlafaxina
AR073265A1 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
ATE442158T1 (de) Oral verabreichte pharmazeutische zusammensetzungen mit einem abgabemittel in mikronisierter form
BR0114100A (pt) Formulações de liberação controlada para administração oral
AR042543A1 (es) Composiciones de anti-histaminicos, descongestivos y drogas anti-inflamatorias no esteroides
AR031679A1 (es) Una composicion farmaceutica
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
AR029588A1 (es) Nueva forma (r)-n-[5-metil-8-(4-metilpiperazina-1-il)-1,2,3,4-tetrahidro-2-naftil]-4-morfolinobenzamida

Legal Events

Date Code Title Description
FC Refusal